Trial
NCT05047523
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Wilson Disease
Intervention
ALXN1840
Why stopped
Sponsor decision to terminate the program
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-23